Financial Data
AZN Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
AZNAstraZeneca PLC
Healthcare / Drug Manufacturers - General
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum74
- Value53
- Quality72
- Risk resilience47
- Sentiment67
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 22, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | $15.38B | $15.29B | $15.5B |
| Gross Profit | $12.86B | $12.61B | $12.39B |
| Operating Income | $3.16B | $4.25B | $2.98B |
| Net Income | $2.51B | $3.08B | $2.33B |
| EPS | $1.6 | $1.99 | $1.51 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Operating Cash Flow | $2.89B | $3.36B | $2.43B | $5.13B |
| Capital Expenditure | -$752.85M | -$1.54B | -$1.05B | -$1.73B |
| Free Cash Flow | $2.13B | $1.82B | $1.38B | $3.41B |
| Net Cash Provided By Operating Activities | $2.89B | $3.36B | $2.43B | $5.13B |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Total Assets | $115.7B | $114.02B | $114.07B |
| Total Debt | $32.25B | $33.95B | $29.65B |
| Cash And Cash Equivalents | — | — | — |
| Total Liabilities | $65.39B | $66.63B | $65.36B |
| Total Stockholders Equity | $50.31B | $47.38B | $48.72B |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| P/E ratio | 29.21 | 24.39 | 30.92 |
| P/B ratio | 5.74 | 6.35 | 5.91 |
| P/S ratio | 18.96 | 19.67 | 18.56 |
| Debt To Equity | 0.64 | 0.72 | 0.61 |
| Free Cash Flow Yield | 0.74% | 0.61% | 0.37% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| P/E ratio | 29.21 | 24.39 | 30.92 | 23.2 |
| P/B ratio | 5.74 | 6.35 | 5.91 | 5.11 |
| P/S ratio | 18.96 | 19.67 | 18.56 | 15.45 |
| Return On Equity | 4.93% | 6.51% | 4.78% | 5.52% |
| Debt To Equity | 0.64 | 0.72 | 0.61 | 0.71 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | 24.08x |
| Pb | 4.96x |
| Gross Margin | 79.27% |
| Operating Margin | 22.69% |
| ROE | 21.68% |
| ROIC | 12.69% |
| Debt To Equity | 0.64 |
| FCF Yield | 3.37% |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Close | $168.45 |
| Volume | 1.85M |
| RSI (14) | 68.71 |
| MACD | 0.86 |
| MACD signal | -0.27 |
| MACD histogram | 1.13 |
| ADX (14) | 15.1 |
| SMA (50) | $162.52 |
| SMA (200) | $180.71 |
| ATR (14) | $3.64 |
| Historical volatility (annualized) | 26.29% |
| Volume (20-day average) | 2.87M |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Resilience score | 47/100 |
| Beta | 0.21 |
| Annual volatility | 27.21% |
| Max Drawdown | -25.71% |
| Sharpe Ratio | 0.01 |
| VaR (95%, 1-day) | -2.47% |
As of Oct 21, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
AZN Financial Data FAQ
What is AstraZeneca PLC's revenue?
AstraZeneca PLC's revenue is one of the core financial data points for AZN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is AstraZeneca PLC's revenue growing?
Revenue growth shows whether AstraZeneca PLC is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is AZN's EPS?
AZN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is AstraZeneca PLC's net income?
AstraZeneca PLC's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does AstraZeneca PLC generate?
Free cash flow shows how much cash AstraZeneca PLC generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does AstraZeneca PLC have?
Cash and debt help frame AZN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.